Skip to main content

Advertisement

SpringerLink
Log in

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer

  • Clinical Trials Report
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fisher B, Foster R, Gardner B, et al.: Relation of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 1983, 52:1551–1557.

    Article  PubMed  CAS  Google Scholar 

  2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Lancet 2005, 365:1687–1717.

  3. Crown J, O’Leary M, Ooi WS: Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 2004, 2:24–32.

    Article  Google Scholar 

  4. De Laurentiis M, Cancello G, D’Agostino D, et al.: Taxanebased combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008, 26:44–53.

    Article  PubMed  Google Scholar 

  5. Henderson IC, Berry DA, Demetri GD, et al.: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21:976–983.

    Article  PubMed  CAS  Google Scholar 

  6. Berry D, Cirrincione C, Henderson IC, et al.: Estrogen receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006, 295:1658–1667.

    Article  PubMed  CAS  Google Scholar 

  7. Hayes DF, Thor AD, Dressler LG, et al.: HER2 and response to paclitaxel in node-positive breast cancer. J Clin Oncol 2007, 357:1496–1506.

    CAS  Google Scholar 

  8. Sparano JA, Wang M, Martino S, et al.: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 358:1663–1671.

    Article  PubMed  CAS  Google Scholar 

  9. Seidman AD, Berry D, Cirrincione C, et al.: Randomized phase III trial of weekly compared with every 3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008, 26:1642–1649.

    Article  PubMed  CAS  Google Scholar 

  10. Citron ML, Berry DA, Cirrincione C, et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003, 21:1431–1439.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Memorial Sloan-Kettering Cancer Center, Breast Cancer Medicine Service, 1275 York Avenue, New York, NY, 10021, USA

    Chau Dang

Authors
  1. Chau Dang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chau Dang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dang, C. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Curr Breast Cancer Rep 1, 1–2 (2009). https://doi.org/10.1007/s12609-009-0001-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-009-0001-9

Keywords

Search

Navigation